Clinical Trials
82 trialsA Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
ModernaTX, Inc.
PanTumor-101
GlaxoSmithKline
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Merck Sharp & Dohme LLC
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
Immatics Biotechnologies GmbH
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Nectin Therapeutics Ltd
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Amgen
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Vividion Therapeutics, Inc.
FLAGSHP-1
Erasca, Inc.
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
University of California, San Diego
KEYNOTE-E12
Shenzhen Ionova Life Sciences Co., Ltd.
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
MK-4700-001
Merck Sharp & Dohme LLC
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Werewolf Therapeutics, Inc.
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Riboscience, LLC.
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Sairopa B.V.
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
BOREALIS-1
Erasca, Inc.
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
Amgen
EIK1001
Eikon Therapeutics
Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Eikon Therapeutics
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
Hummingbird Bioscience
KEYVIBE-001
Merck Sharp & Dohme LLC
MK-4464-001
Merck Sharp & Dohme LLC
MK-4830-001
Merck Sharp & Dohme LLC
Study of KBA1412 in Participants With Advanced Solid Malignant Tumors
Kling Biotherapeutics B.V.
AURORAS-1
Erasca, Inc.
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
MK-0482-001
Merck Sharp & Dohme LLC
MK-4280-001
Merck Sharp & Dohme LLC
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Astellas Pharma Inc
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Inspirna, Inc.
Meteor 1
GlaxoSmithKline
V941-001
Merck Sharp & Dohme LLC
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics Inc
MK-8353-013
Merck Sharp & Dohme LLC
IVY
Eli Lilly and Company